skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis

Review

(2026) Views  (932) Full article downloads

Authors: Patricia B Williams, Elizabeth Crandall, John D Sheppard

Published Date September 2010 Volume 2010:4 Pages 993 - 1001
DOI: http://dx.doi.org/10.2147/OPTH.S13479

Patricia B Williams1,2, Elizabeth Crandall2, John D Sheppard1,2

1Thomas R Lee Center for Ocular Pharmacology, 2Department of Ophthalmology, Eastern Virginia Medical School, Norfolk, A, USA

Abstract: Over 50% of patients who seek treatment for allergies present with ocular ­symptoms. Our current ability to control ocular allergic symptoms is greater than ever before. Newer dual-acting topical eyedrops attack multiple facets of the allergic cascade. Azelastine has antihistaminic effects providing immediate relief, mast cell stabilization providing early-phase intervention, and inhibition of expression and activation of anti-inflammatory mediators which characterize the late phase of the immune reaction. The ophthalmic eyedrop formulation is approved for treatment of allergic conjunctivitis in adults and children aged over 3 years. In clinical trials comparing azelastine with other dual-acting eyedrops, such as levocabastine and olopatadine, azelastine was reported to be slightly less efficacious and to sting briefly upon administration. Even so, many patients experienced the full benefit of symptom relief, and preferred azelastine. As a broad-spectrum drug, azelastine offers many desirable properties for management of ocular allergies. Because it can often produce maximal effect with just twice-daily dosing, azelastine is a particularly good choice for the allergic population in whom minimizing exposure to topical products and preservatives is a key concern.

Keywords: allergic conjunctivitis, dual acting anti-inflammatory, H1 receptor antagonism, mast cell stabilization, inflammatory mediator inhibition







Readers of this article also read:

Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
Difluprednate ophthalmic emulsion 0.05% (Durezol®) administered two times daily for managing ocular inflammation and pain following cataract surgery
Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%
Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis
Evaluation of olopatadine 0.2% in the complete prevention of ocular itching in the conjunctival allergen challenge model
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy